Market Cap 290.72B
Revenue (ttm) 54.07B
Net Income (ttm) 7.04B
EPS (ttm) N/A
PE Ratio 20.17
Forward PE 17.99
Profit Margin 13.01%
Debt to Equity Ratio 0.67
Volume 3,116,567
Avg Vol 6,638,534
Day's Range N/A - N/A
Shares Out 1.55B
Stochastic %K 94%
Beta 0.34
Analysts Strong Sell
Price Target $204.33

Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 44 20 3749 5000
Address:
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom
MidwestWhale
MidwestWhale Apr. 3 at 9:55 PM
$AZN watching AstraZeneca this week for a big pop! Options market indicates a big move is coming! $XRP.X $BTC.X $AMC
1 · Reply
Ro_Patel
Ro_Patel Apr. 3 at 4:26 PM
3rd proposed class action, filed on March 30, 2026, is Barone v. Tempus AI. This lawsuit significantly escalates the legal pressure on $TEM by explicitly naming pharmaceutical giant $AZN as a defendant for its role in the alleged data mining scheme In early 2026, Tempus AI was hit w/ multiple class action lawsuits—including Nash v. Tempus AI & Vargas v. Tempus AI—alleging the illegal mining & disclosure of highly sensitive genetic data from millions of patients. The litigation, filed in the US District Court for the Northern District of Illinois, focuses on Tempus’s Feb 2025 acquisition of Ambry Genetics for $600M Plaintiffs allege Tempus "compelled" Ambry to disclose its massive genetic database without notifying patients or obtaining the express written consent required by state law Primary legal battleground is the Illinois Genetic Information Privacy Act (GIPA) - plaintiffs can seek $2,500 for negligent violations & up to $15,000 for intentional or reckless violations per instance
1 · Reply
Jay_Bingo
Jay_Bingo Apr. 2 at 8:34 PM
$IOVA $AZN $NVS Can buy Iovance with US manufacturing already existing so no or minimal tariffs for pricing. 10 billion buyout is all it takes. $24 A share.
0 · Reply
trenddetector
trenddetector Apr. 2 at 6:29 PM
$AZN Share this site with anyone that has cancer, or has a friend or family member with cancer, and is searching for options. A great resource for those confused about approved treatments and trials that are enrolling. https://nimble-frangollo-81ff5e.netlify.app/#
0 · Reply
KingDobieGillisDa1st
KingDobieGillisDa1st Apr. 2 at 6:29 PM
*** We have News*** $AZN 🤑🤑🤑🤑 https://www.contractpharma.com/breaking-news/astrazeneca-enters-agreement-to-lower-u-s-drug-prices/
1 · Reply
AStrokeOfLuck
AStrokeOfLuck Apr. 2 at 6:16 PM
1 · Reply
maikl_211
maikl_211 Apr. 2 at 2:28 PM
0 · Reply
maikl_211
maikl_211 Apr. 2 at 2:25 PM
0 · Reply
TradeTracs
TradeTracs Apr. 2 at 2:22 PM
$AZN just posted a Phase 3 win — Imfinzi combo succeeds in hepatocellular carcinoma (HCC). That's the most common liver cancer. Late-stage trial wins are rare catalysts. 👀 Stock sitting at $200.73, trading well above SMA20 ($191.12) and SMA50 ($193.68). RSI at 60.95 — momentum building but not overbought. Up 10.99% this quarter already. 52-week high is $212.71 — that's the level to watch for a breakout. HCC approval could be a meaningful revenue driver for $ESALF too. #AZN #Biotech #Oncology
0 · Reply
maikl_211
maikl_211 Apr. 2 at 12:46 PM
0 · Reply
Latest News on AZN
Trump Administration Unveils Up to 100% Tariff on Branded Drugs

Thu, 02 Apr 2026 17:34:00 -0400 - 3 days ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs


AstraZeneca stock jumps as COPD drug trial win surprises market

Fri, 27 Mar 2026 10:55:14 -0400 - 9 days ago

AstraZeneca stock jumps as COPD drug trial win surprises market


Stocks to Watch: Unity, Carnival, AstraZeneca

2026-03-27T14:00:29.000Z - 9 days ago

Stocks to Watch: Unity, Carnival, AstraZeneca


AstraZeneca Zips Higher On Its Double Win In COPD Treatment

2026-03-27T13:01:07.000Z - 9 days ago

AstraZeneca Zips Higher On Its Double Win In COPD Treatment


AstraZeneca drug reduces COPD flare ups in late-stage trials

Fri, 27 Mar 2026 03:18:47 -0400 - 9 days ago

AstraZeneca drug reduces COPD flare ups in late-stage trials


Final Trade: AZN, VIX, IWM

2026-03-26T22:06:21.000Z - 10 days ago

Final Trade: AZN, VIX, IWM


TrumpRx lists many medicines at prices higher than paid in UK

Wed, 18 Mar 2026 14:23:38 -0400 - 18 days ago

TrumpRx lists many medicines at prices higher than paid in UK


Challenges for AstraZeneca (AZN) Amid Drug Pricing Claims

2026-03-18T15:26:42.000Z - 18 days ago

Challenges for AstraZeneca (AZN) Amid Drug Pricing Claims


AZN Stock Experiences Slight Dip in Morning Trading

2026-03-12T15:51:09.000Z - 24 days ago

AZN Stock Experiences Slight Dip in Morning Trading


AstraZeneca (AZN) Refutes Takeover Speculation

2026-03-12T15:27:09.000Z - 24 days ago

AstraZeneca (AZN) Refutes Takeover Speculation


Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline

Thu, 12 Mar 2026 06:46:52 -0400 - 24 days ago

Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline


Top 3 Health Care Stocks That May Collapse This Quarter

Feb 18, 2026, 9:04 AM EST - 6 weeks ago

Top 3 Health Care Stocks That May Collapse This Quarter

GERN MASI


AstraZeneca PLC (AZN) Q4 2025 Earnings Call Transcript

Feb 10, 2026, 12:44 PM EST - 7 weeks ago

AstraZeneca PLC (AZN) Q4 2025 Earnings Call Transcript


AstraZeneca results: FY and Q4 2025

Feb 10, 2026, 7:00 AM EST - 7 weeks ago

AstraZeneca results: FY and Q4 2025


AstraZeneca Forecasts Continued Growth on Pipeline Strength

Feb 10, 2026, 2:34 AM EST - 7 weeks ago

AstraZeneca Forecasts Continued Growth on Pipeline Strength


AstraZeneca profit climbs on cancer and heart drug demand

Feb 10, 2026, 2:24 AM EST - 7 weeks ago

AstraZeneca profit climbs on cancer and heart drug demand


Drugmaker AstraZeneca forecasts sales and profit growth in 2026

Feb 10, 2026, 2:06 AM EST - 7 weeks ago

Drugmaker AstraZeneca forecasts sales and profit growth in 2026


AstraZeneca begins trading on the New York Stock Exchange

Feb 2, 2026, 7:00 AM EST - 2 months ago

AstraZeneca begins trading on the New York Stock Exchange


AstraZeneca to delist from Nasdaq, join NYSE in February

Jan 20, 2026, 2:21 AM EST - 2 months ago

AstraZeneca to delist from Nasdaq, join NYSE in February


AstraZeneca to acquire Modella AI to speed oncology drug research

Jan 13, 2026, 12:10 PM EST - 2 months ago

AstraZeneca to acquire Modella AI to speed oncology drug research


AstraZeneca: Oncology Dominance Justifies New All-Time Highs

Jan 10, 2026, 10:00 AM EST - 3 months ago

AstraZeneca: Oncology Dominance Justifies New All-Time Highs


MidwestWhale
MidwestWhale Apr. 3 at 9:55 PM
$AZN watching AstraZeneca this week for a big pop! Options market indicates a big move is coming! $XRP.X $BTC.X $AMC
1 · Reply
Ro_Patel
Ro_Patel Apr. 3 at 4:26 PM
3rd proposed class action, filed on March 30, 2026, is Barone v. Tempus AI. This lawsuit significantly escalates the legal pressure on $TEM by explicitly naming pharmaceutical giant $AZN as a defendant for its role in the alleged data mining scheme In early 2026, Tempus AI was hit w/ multiple class action lawsuits—including Nash v. Tempus AI & Vargas v. Tempus AI—alleging the illegal mining & disclosure of highly sensitive genetic data from millions of patients. The litigation, filed in the US District Court for the Northern District of Illinois, focuses on Tempus’s Feb 2025 acquisition of Ambry Genetics for $600M Plaintiffs allege Tempus "compelled" Ambry to disclose its massive genetic database without notifying patients or obtaining the express written consent required by state law Primary legal battleground is the Illinois Genetic Information Privacy Act (GIPA) - plaintiffs can seek $2,500 for negligent violations & up to $15,000 for intentional or reckless violations per instance
1 · Reply
Jay_Bingo
Jay_Bingo Apr. 2 at 8:34 PM
$IOVA $AZN $NVS Can buy Iovance with US manufacturing already existing so no or minimal tariffs for pricing. 10 billion buyout is all it takes. $24 A share.
0 · Reply
trenddetector
trenddetector Apr. 2 at 6:29 PM
$AZN Share this site with anyone that has cancer, or has a friend or family member with cancer, and is searching for options. A great resource for those confused about approved treatments and trials that are enrolling. https://nimble-frangollo-81ff5e.netlify.app/#
0 · Reply
KingDobieGillisDa1st
KingDobieGillisDa1st Apr. 2 at 6:29 PM
*** We have News*** $AZN 🤑🤑🤑🤑 https://www.contractpharma.com/breaking-news/astrazeneca-enters-agreement-to-lower-u-s-drug-prices/
1 · Reply
AStrokeOfLuck
AStrokeOfLuck Apr. 2 at 6:16 PM
1 · Reply
maikl_211
maikl_211 Apr. 2 at 2:28 PM
0 · Reply
maikl_211
maikl_211 Apr. 2 at 2:25 PM
0 · Reply
TradeTracs
TradeTracs Apr. 2 at 2:22 PM
$AZN just posted a Phase 3 win — Imfinzi combo succeeds in hepatocellular carcinoma (HCC). That's the most common liver cancer. Late-stage trial wins are rare catalysts. 👀 Stock sitting at $200.73, trading well above SMA20 ($191.12) and SMA50 ($193.68). RSI at 60.95 — momentum building but not overbought. Up 10.99% this quarter already. 52-week high is $212.71 — that's the level to watch for a breakout. HCC approval could be a meaningful revenue driver for $ESALF too. #AZN #Biotech #Oncology
0 · Reply
maikl_211
maikl_211 Apr. 2 at 12:46 PM
0 · Reply
DonCorleone77
DonCorleone77 Apr. 2 at 12:14 PM
$JNJ $LLY $MRK $PFE $AZN Trump administration readying new pharmaceutical tariffs, FT reports The Trump administration is preparing 100% tariffs on certain imported medicines, targeting companies that have not committed to increasing U.S. manufacturing, The Financial Times' Aime Williams reports. The move follows earlier threats to impose such levies on branded or patented drugs, while companies including Pfizer (PFE), AstraZeneca (AZN), and Novo Nordisk (NVO) have secured exemptions by pledging greater U.S. investment and price reductions. Other publicly traded companies in the space include Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
0 · Reply
DonCorleone77
DonCorleone77 Apr. 2 at 12:08 PM
$AZN AstraZeneca Phase III EMERALD-3 trial showed meaningful improvement in endpoint Positive high-level results from the EMERALD-3 Phase III trial showed AstraZeneca's Imfinzi in combination with Imjudo, lenvatinib and transarterial chemoembolisation, TACE, demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival, PFS, versus TACE alone for patients with unresectable hepatocellular carcinoma, HCC, eligible for embolisation. At this interim analysis for overall survival, OS, a key secondary endpoint, this combination also demonstrated a trend toward OS improvement versus TACE alone. Patients in the investigational arms were treated with the STRIDE regimen, with or without lenvatinib, before TACE, and then alongside TACE.
0 · Reply
EmSol
EmSol Apr. 1 at 4:08 PM
$AZN next week they will got approval for blood pressure and it will be a blockbuster moving the stock at $225
1 · Reply
gargoyl
gargoyl Apr. 1 at 3:07 PM
$BLRX 👀 BiolineRx playing with big boyz … 🎯 $18.99 $MRK $AZN
0 · Reply
NorthStarStats
NorthStarStats Apr. 1 at 1:45 AM
Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $CSX Score 100, $NUVL Score 100, $AZN Score 100, $WAB Score 100, $PCVX Score 98
0 · Reply
Quantumup
Quantumup Mar. 31 at 6:46 PM
Stifel reiterated $CMPX Buy; $12 Ahead of Upcoming Data. $AZN $MRK BMY PFE RLAY Here's what Stifel said in its note to investors: https://x.com/Quantumup1/status/2039050783631482911?s=20
0 · Reply
Chipwars
Chipwars Mar. 31 at 5:32 PM
$AZN AstraZeneca drug for rare bone disease shows positive trial results : https://www.sharecast.com/news/news-and-announcements/astrazeneca-drug-for-rare-bone-disease-shows-positive-trial-results--22216535.html
0 · Reply
Chipwars
Chipwars Mar. 31 at 5:12 PM
$AZN yet more good news : https://www.astrazeneca.com/media-centre/press-releases/2026/efzimfotase-alfa-demonstrated-positive-results-global-phase-iii-clinical-programme-hypophosphatasia.html
0 · Reply
Eliza1
Eliza1 Mar. 30 at 7:29 PM
0 · Reply
Chipwars
Chipwars Mar. 30 at 2:47 PM
$AZN ASTRAZENECA : JP Morgan gives a Buy rating £1600
0 · Reply
Chipwars
Chipwars Mar. 30 at 2:34 PM
$AZN Guggenheim analyst Seamus Fernandez maintains $ASTRAZENECA (AZN.US)$ with a buy rating, and adjusts the target price from $211.93 to $218.55. According to TipRanks data, the analyst has a success rate of 60.7% and a total average return of 25.8% over the past year.
0 · Reply
Chipwars
Chipwars Mar. 30 at 2:16 PM
$AZN TD Cowen reiterated a Buy rating and $240.00 price target on AstraZeneca following positive Phase III trial results for tozorakimab in chronic obstructive pulmonary disease. The stock has surged 30% over the past year and currently trades at $188.42, with InvestingPro analysis suggesting the pharmaceutical giant remains undervalued relative to its Fair Value.
0 · Reply